Relationship between NT-proBNP and the ejection fraction during intensive care variety in polytrauma patients with concomitant cardiac disorder
Keywordspolytrauma, heart failure, NT-proBNP, ejection fraction
The aim. To research the impact of chronic heart failure within different origin in case of polytrauma without myocardial injury.
Materials and methods. The study the analyzed results of intensive care in 95 patients with polytrauma between the ages of 25 and 83. All patients were divided into 3 groups. Group C included 29 patients without chronic heart failure (CHF), groups C - 33 patients with CHF, the presence which was confirmed by the level of NT-proBNP more than 100 pg/ml, group E - 33 patients with CHF. Patients of groups K and C received standard intensive care, patients of group E additionally received ethylmethylhydroxypyridine succinate (EMGPS). The study was carried out at three stages: during admission to the hospital, at the 3rd and 7th day. During admission, the level of Th I was determined in order to exclude traumatic or other acute myocardial lesions. At a concentration of Tn I more than 0.3 ng/ml, patients were not included in the study.
Results. During admission, NT-proBNP level in all K-group patients did not exceed 87 pg/ml throughout the study. The ejection fraction (EF) was averaged 53,7±3,4%. The NT-proBNP dynamics were as followed by 116.4±7.0, 114.4±7.4, 109.1±8.5 pg/ml. The NT-proBNP and EF correlation coefficient was according to the stages -0.84±0.06, -0.74±0.08, -0.68±0.09. The value of the EF at hospitalization in group C was 47.9±4.7%, on the 3rd day 52.2±5.2% (p < 0.001), and by 7th - until 56.8±6.9% (p < 0.001). NT-proBNP level in E patients: 119.2±10.8, 113.2±8.1 (p= 0.02), 65.2±23.3 (p < 0.0001). At stage 1 and 2, a strong negative correlation effect was observed (-0.78±0.07 and -0.77±0.07, accordingly), at the 3 stage the communication disappeared (0.07±0.17). Within admission EF level was 47.5±6.9 %.
Conclusions. The level of NT-proBNP authentically reflects the relationship with chronic heart failure. There is also a strong correlation between NT-proBNP and EF. Therefore, it is clear from the study that NT-proBNP has not undergone changes in group K (87 pg/ml), in contrast to patients of groups C (116.4±7.0,114.4±7.4, 109.1±8.5 pg/ml) and E (119.2±10.8, 113.2±8.1 (p =0.02), 65.2±23.3 (p < 0.0001) who had concomitant disorder such as chronic heart failure.
ATLS Subcommittee, American College of Surgeons' Committee on Trauma, International ATLS working group. Advanced trauma life support (ATLS ®): the ninth edition. J Trauma Acute Care Surg. 2013;74(5):1363-1366.
Loskutov O.A, Druzhyna A.N, Kolesnikov V.G, Loskutov D.O. Taktika intensivnoj terapii pri massivnykh travmaticheskikh krovotecheniiakh [Intensive care tactics in case of profuse injury hemorrhage]. Meditsina neotlozhnykh sostoianij [J Emergency medicine]. 2016;4(75):196.
Kobeliatskyi Yu.Yu, Yovenko I.A, Tsariov A.V, Kuz’mova Ye.A, Perederij M.N. Intensivnaia terapiia politravmy s pozitsiiej sovremennykh mezhdunarodnykh rekomendatsij [Intensive care of polytrauma from the perspective of current international guidelines]. Meditsina neotlozhnykh sostoianij [J Emergency medicine]. 2017;7(54):9-14.
Ministry of development of economy and trade of Ukraine. Tsili staloho rozvytku: Ukraiina. Natsional’na dopovid’ [Purposes of sustainable development: Ukraine. National report]. 2016 Apr.; 24-31.
DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916; 17:863-71.
Nikonov V.V., Nudga A.N. Organism system reaction to aggression. Medical practice. 1997:5:10-4.
Lugrin J., Robenblat-Velyn N., Papanov R., Lyaud L. Biological chemistry. 2014; 395 (2):203-30. Doi:10.1515/hsz-2013-0241
Sereda S., Sanchez S., Clement B., Vasquez. A., Iradi A., El Armani F., Bediaga A., South G. Achievements in Experimental Medicine and Biology. 2014, 824:5-17.
Jambh R., Dimri U., Gupta V., Rotore R., Medical World 2013;6(5):271-3.
Kireyev I., Orobets V., Sevastianova O., Shakhova V., Agarkov A. Research Journal of Pharmaceutical, Biological and Chemical Sciences 2018; 9(5):2031-36.
How to Cite
Copyright (c) 2021 Svitlana Lutska, Yulia Volkova, Kostiantyn Mykhnevych
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.The periodical offers access to content in the Open Access system under the Creative Commons non-exclusive license (CC BY-ND 4.0).
Number of views and downloads: 33
Number of citations: 0